Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibolone and alpha-lipoic acid for climacteric syndrome
ACTRN12611000200987Phase 4Completed
- Sponsor
- Universidade Federal do Rio Grande do Norte
- Start
- Oct 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tibolone and alpha-lipoic acid in climacteric and menopause (4 arms), sponsored by Universidade Federal do Rio Grande do Norte. Primary endpoints: Climacteric symptoms, Oxidative stress and antioxidant enzyme activity and 1 more. Started Oct 2008; status: completed.
02
Drugs
tibolonealpha-lipoic acid
03
Conditions
climactericmenopause
Beyond the preview
Go deeper on ACTRN12611000200987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000200987.